AIHealthcare

InformAI, Inc. is a privately held healthcare informatics and AI company based in Houston’s Texas Medical Center. Founded in 2017, it develops fit-for-purpose clinical software using machine learning, deep learning, medical-image classification, predictive analytics, and clinical decision support. Its stated focus areas include radiation oncology, diagnostic imaging, organ transplantation, and surgical or patient-outcome analytics. Its portfolio includes RadOncAI, an AI-assisted radiation-therapy dose-planning product for head-and-neck cancers; TransplantAI, a donor-recipient and organ-allocation informatics platform; and SinusAI, a CT-imaging diagnostic product in development. The company has described collaborations with healthcare organizations, physician groups, imaging/PACS companies, Texas Medical Center institutions, and technology programs operated by NVIDIA, Microsoft, and Amazon. Publicly available information indicates a small private company with approximately 10–12 employees; its market position is that of an early-stage, specialized clinical-AI and software-as-a-medical-device vendor rather than a broad-based healthcare platform. InformAI announced FDA 510(k) clearance for RadOncAI in June 2026, enabling U.S. marketing and distribution, although independent information on commercial revenue, customer count, market share, and valuation is not publicly available.